EP300 and cancer: In conclusion, our RT- and ChIP-qPCR analysis confirmed the observed p53-mediated response in HME-treated HepG2 cells and linked it with increased recruitment of p53 and p300 at the chromatin of the upregulated loci, as part of an overall anti-cancer response that was observed in this cell line, in contrast to the Ls174 cells in which HME treatment was mostly associated with metabolic effects (Fig. 6).